UBS O'Connor’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

UBS O'Connor’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-16,000	Closed	-$133K	–	670
2023 Q2	$133K	Buy	+16,000	New	+$1.51M	﹤0.01%	487

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS O'Connor's RETA Position: Q3 2023 in Review

UBS O'Connor sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,000 shares — an estimated $510K sold.

UBS O'Connor first reported a position in RETA in Q3 2017 and held it in 5 quarters. The position peaked at $2.59M in Q3 2017. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

UBS O'Connor reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
UBS O'Connor sold 5,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $510K.
UBS O'Connor first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 5 quarters.
UBS O'Connor's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.59M in Q3 2017.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.